We are live on
!
Find out more
BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Est. Return
64.18%
This Fund
S&P 500
This Quarter
Est. Return
+17.5%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$224M
AUM Growth
–
Cap. Flow
+$210M
Cap. Flow
% of AUM
93.61%
Top 10 Holdings %
Top 10 Hldgs %
51.23%
Holding
23
New
23
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Cooper Companies
COO
|
+$12M |
| 2 |
Perrigo
PRGO
|
+$11.7M |
| 3 |
Smith & Nephew
SNN
|
+$11.4M |
| 4 |
Centene
CNC
|
+$10.7M |
| 5 |
Biogen
BIIB
|
+$10.5M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 78.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Perrigo
PRGO
$1.54B
| $12.5M | 5.59% |
+75,000
| New | +$11.7M |
|
|
2
Smith & Nephew
SNN
$13.2B
| $12.5M | 5.56% |
+339,500
| New | +$11.4M |
|
|
RCPT
3
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $12.3M | 5.46% |
+100,000
| New | +$10.1M |
|
|
4
Cooper Companies
COO
$14.3B
| $12.2M | 5.42% |
+300,000
| New | +$12M |
|
|
5
Centene
CNC
$31.5B
| $11.9M | 5.33% |
+460,000
| New | +$10.7M |
|
|
MDCO
6
DELISTED
Medicines Co
MDCO
| $11.1M | 4.94% |
+400,000
| New | +$9.91M |
|
|
7
Biogen
BIIB
$30.8B
| $11M | 4.92% |
+32,500
| New | +$10.5M |
|
8
Viatris
VTRS
$20.2B
| $11M | 4.9% |
+195,000
| New | +$10.5M |
|
9
Teva Pharmaceuticals
TEVA
$37.5B
| $10.4M | 4.62% |
+180,000
| New | +$10M |
|
|
SHPG
10
DELISTED
Shire pic
SHPG
| $10.1M | 4.5% |
+47,500
| New | +$10.1M |
|
|
MNK
11
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $9.9M | 4.42% |
+100,000
| New | +$9.2M |
|
12
Molina Healthcare
MOH
$11.7B
| $9.63M | 4.3% |
+180,000
| New | +$8.72M |
|
|
WMGI
13
DELISTED
Wright Medical Group Inc
WMGI
| $9.2M | 4.1% |
+342,500
| New | +$10M |
|
|
HNT
14
DELISTED
HEALTH NET INC
HNT
| $9.1M | 4.06% |
+170,000
| New | +$8.37M |
|
15
Humana
HUM
$46.4B
| $8.98M | 4% |
+62,500
| New | +$8.54M |
|
|
SIRO
16
DELISTED
SIRONA DENTAL SYSTEMS INC COM STK
SIRO
| $8.96M | 3.99% |
+102,500
| New | +$8.46M |
|
17
Zoetis
ZTS
$32.2B
| $8.82M | 3.93% |
+205,000
| New | +$8.32M |
|
|
CTRX
18
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $8.28M | 3.69% |
+160,000
| New | +$7.52M |
|
19
Vertex Pharmaceuticals
VRTX
$123B
| $8.02M | 3.58% |
+67,500
| New | +$7.6M |
|
20
Edwards Lifesciences
EW
$50.6B
| $7.64M | 3.41% |
+360,000
| New | +$7.23M |
|
|
GEVA
21
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $7.42M | 3.31% |
+80,000
| New | +$6.31M |
|
22
Intuitive Surgical
ISRG
$142B
| $6.88M | 3.07% |
+117,000
| New | +$6.52M |
|
23
Globus Medical
GMED
$11B
| $6.54M | 2.91% |
+275,000
| New | +$6.09M |
|
Similar funds
BCM
RJA
RP
ACPVT
SFA
KL
KFS
FHC
Blue Jay Capital Management's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Blue Jay Capital Management, which disclosed 23 positions worth $224M. Its ten largest holdings account for 51% of the portfolio.
Its largest position is Cooper Companies: 300,000 shares worth $12.2M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets.
- Blue Jay Capital Management's largest Q4 2014 buy was Cooper Companies: 300,000 shares worth $12.2M.
- Blue Jay Capital Management's ten largest holdings make up 51% of its $224M portfolio in Q4 2014.
- Blue Jay Capital Management disclosed 23 positions in Q4 2014, its first 13F filing on record.
Based on Blue Jay Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.